Volker Thiel

University of Bern - Institute of Virology and Immunology

Gesellschaftsstrasse 49

Bern, BERN 3001

Switzerland

SCHOLARLY PAPERS

2

DOWNLOADS

59

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Development of Safe and Highly Protective Live-Attenuated SARS-CoV-2 Vaccine Candidates by Genome Recoding

Number of pages: 43 Posted: 10 Feb 2021
Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Tierpathologie, University of Bern - Institute of Virology and Immunology, University of Bern - Institute of Virology and Immunology, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, University of Bern - Department of Infectious Diseases and Pathobiology, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, Free University of Berlin (FUB) - Institut für Virologie, University of Bern - Department of Infectious Diseases and Pathobiology, Free University of Berlin (FUB) - Institut für Tierpathologie, University of Bern - Institute of Virology and Immunology, Free University of Berlin (FUB) - Institut für Virologie and Free University of Berlin (FUB) - Institut für Virologie
Downloads 34 (605,788)

Abstract:

Loading...

coronavirus, SARS-CoV-2, COVID-19, live attenuated vaccine, genome recoding, codon pair deoptimization, synthetic attenuated virus engineering, Syrian hamster

2.

A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of Concern

Number of pages: 38 Posted: 12 May 2021
University of Lausanne - Swiss Vaccine Research Institute, Ecole Polytechnique Fédérale de Lausanne - Global Health Insitute, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, Ecole Polytechnique Fédérale de Lausanne - Global Health Insitute, Ecole Polytechnique Fédérale de Lausanne - School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne - School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne - School of Life Sciences, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, University of Lausanne - Service of Immunology and Allergy, KU Leuven - Laboratory of Virology and Chemotherapy, KU Leuven - Laboratory of Virology and Chemotherapy, KU Leuven - Laboratory of Virology and Chemotherapy, KU Leuven - Laboratory of Virology and Chemotherapy, Utrecht University - Virology Section, Utrecht University - Virology Section, Abbvie Bioresearch Center, KU Leuven - Laboratory of Virology and Chemotherapy, University of Bern - Institute of Virology and Immunology, Henri-Mondor Hospital - Vaccine Research Institute, University of Claude Bernard Lyon 1 - Inserm, Ecole Polytechnique Fédérale de Lausanne - Global Health Insitute and University of Lausanne - Service of Immunology and Allergy
Downloads 25 (664,274)

Abstract:

Loading...

SARS-CoV-2, neutralizing antibodies, Variants of concern